$4.60
2.68% yesterday
Nasdaq, Sep 11, 10:04 pm CET
ISIN
US9216591084
Symbol
VNDA

Vanda Pharmaceuticals Inc. Stock price

$4.60
+0.41 9.79% 1M
-0.38 7.63% 6M
-0.19 3.97% YTD
-0.32 6.50% 1Y
-5.70 55.34% 3Y
-5.14 52.77% 5Y
-8.73 65.49% 10Y
-5.08 52.48% 20Y
Nasdaq, Closing price Thu, Sep 11 2025
+0.12 2.68%
ISIN
US9216591084
Symbol
VNDA
Industry

Key metrics

Basic
Market capitalization
$271.8m
Enterprise Value
$-48.4m
Net debt
positive
Cash
$325.6m
Shares outstanding
59.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.3 | 1.2
EV/Sales
negative | negative
EV/FCF
0.7
P/B
0.6
Financial Health
Equity Ratio
82.1%
Return on Equity
-3.5%
ROCE
-20.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$203.5m | $229.5m
EBITDA
$-93.8m | $-38.0m
EBIT
$-100.8m | $-140.6m
Net Income
$-66.9m | $-108.9m
Free Cash Flow
$-65.9m
Growth (TTM | estimate)
Revenue
11.8% | 15.5%
EBITDA
-242.7% | -13.9%
EBIT
-210.4% | -245.9%
Net Income
-513.0% | -476.0%
Free Cash Flow
-1,085.4%
Margin (TTM | estimate)
Gross
94.4%
EBITDA
-46.1% | -16.6%
EBIT
-49.6%
Net
-32.9% | -47.4%
Free Cash Flow
-32.4%
More
EPS
$-1.1
FCF per Share
$-1.1
Short interest
8.1%
Employees
368
Rev per Employee
$540.0k
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
78%
Hold
22%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
203 203
12% 12%
100%
- Direct Costs 11 11
10% 10%
6%
192 192
13% 13%
94%
- Selling and Administrative Expenses 192 192
62% 62%
94%
- Research and Development Expense 94 94
20% 20%
46%
-94 -94
243% 243%
-46%
- Depreciation and Amortization 7.01 7.01
37% 37%
3%
EBIT (Operating Income) EBIT -101 -101
210% 210%
-50%
Net Profit -67 -67
513% 513%
-33%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Positive
Seeking Alpha
14 days ago
Vanda Pharma's revenue growth is driven by Fanapt's label expansion to bipolar I disorder, offsetting declines in HETLIOZ and PONVORY sales. Upcoming catalysts include Bysanti's PDUFA date for bipolar I/schizophrenia (Feb 2026) and phase 3 data for MDD, plus tradipitant's motion sickness PDUFA (Dec 2025). Vanda's pipeline features a selective JAK2 inhibitor for polycythemia vera, recently grant...
Neutral
PRNewsWire
15 days ago
WASHINGTON , Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in September 2025: The Cantor Global Healthcare Conference 2025 in New York City on Wednesday, September 3, 2025. A corporate presentation is scheduled for 3:55 p.m.
Neutral
PRNewsWire
15 days ago
WASHINGTON , Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera (PV). PV is a chronic myeloproliferative disorder characterized by aberrant hematopoiesis of myeloid...
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 368
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today